脂质体药物体内过程研究进展  

Advances in the Study of in Vivo Processes of Liposomal Drugs

作　　者：刘梦园 钱隽 占昌友 LIU Mengyuan;QIAN Jun;ZHAN Changyou(Ministry of Education Key Laboratory of Smart Drug Delivery,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Pharmacology,School of Basic Medical Sciences,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学药学院智能化递药教育部重点实验室,上海201203 [2]复旦大学基础医学院药理学系,上海200032

出　　处：《药学进展》2024年第10期735-746,共12页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金(No.32330058,No.82273866)。

摘　　要：得益于优良的生物相容性、低毒性和低免疫原性,脂质体已被广泛用于抗肿瘤药物、抗感染药物等高效递送。尽管涉及脂质体药物的新技术和新类型不断涌现,但其体内过程尚未完全明晰,极大限制了脂质体药物的临床转化和应用。揭示脂质体药物体内血液循环、生物分布、代谢和排泄等过程,全面阐释机体对该过程的调控作用与机制,发掘潜在构效关系,将助力脂质体药物合理设计,加快临床转化进程,助推临床精准应用。重点从脂质体药物体内过程、影响因素和调控策略三方面进行综述,期望为脂质体药物相关研究提供参考。Due to their excellent biocompatibility,low toxicity,and minimal immunogenicity,liposomes have been extensively utilized for the efficient delivery of antitumor agents,antimicrobial agents,among many others.However,despite the advancement in liposome technologies,the in vivo behaviors of liposomes remain insufficiently understood,posing significant challenges to their clinical translation and application.A comprehensive understanding of the processes involved in blood circulation,biodistribution,metabolism,and excretion of liposomal therapeutics—along with a thorough elucidation of the underlying regulatory mechanisms and potential'composition-efficacy'relationships—would greatly aid in the rational design of liposome-based therapies.This review provides an overview of the in vivo delivery processes,influencing factors,and regulatory strategies of liposomal drugs,serving as reference for future research in the field.

关 键 词：脂质体 蛋白冠 体内过程 生物学效应 

分 类 号：R944[医药卫生—药剂学]